Market Research

Cancer Supportive Care Drugs Market {Drug Class: G-CSFs (Granulocyte Colony-Stimulating Factor), ESAs (Erythropoiesis Stimulating Agent), Antiemetics, Bisphosphonates, Opioids, NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), and Others (Topicals, etc.)} -

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 150 Pages Transparency Market Research Pvt. Ltd. January, 2024 TNPR18580332
Best Price Guarantee
Price from $5,795
Length 150 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date January, 2024
SKU TNPR18580332

Cancer Supportive Care Drugs Market {Drug Class: G-CSFs (Granulocyte Colony-Stimulating Factor), ESAs (Erythropoiesis Stimulating Agent), Antiemetics, Bisphosphonates, Opioids, NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), and Others (Topicals, etc.)} - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Cancer Supportive Care Drugs Market – Scope of Report

TMR’s report on the global cancer supportive care drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cancer supportive care drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cancer supportive care drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cancer supportive care drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cancer supportive care drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cancer supportive care drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cancer supportive care drugs market.

The report delves into the competitive landscape of the global cancer supportive care drugs market. Key players operating in the global cancer supportive care drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cancer supportive care drugs market profiled in this report.

Key Questions Answered in Global cancer supportive care drugs market Report
  • What is the sales/revenue generated by wearable injectors across all regions during the forecast period?
  • What are the opportunities in the global cancer supportive care drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Cancer Supportive Care Drugs Market – Research Objectives and Research Approach

The comprehensive report on the global cancer supportive care drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cancer supportive care drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cancer supportive care drugs market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Supportive Care Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution/ Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Key Drug Class/Brand Analysis
5.2. Top 3 Players Operating in the Market Space
5.3. Disease Prevalence and Incidence
5.4. COVID Impact Analysis
6. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Class, 2017-2031
6.3.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
6.3.2. ESAs (Erythropoiesis Stimulating Agent)
6.3.3. Antiemetics
6.3.4. Bisphosphonates
6.3.5. Opioids
6.3.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
6.3.7. Others (Topicals, etc.)
6.4. Market Attractiveness By Drug Class
7. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Indication, 2017-2031
7.3.1. Lung Cancer
7.3.2. Breast Cancer
7.3.3. Prostate Cancer
7.3.4. Liver Cancer
7.3.5. Bladder Cancer
7.3.6. Leukemia
7.3.7. Others (Ovarian Cancer, Melanoma, etc.)
7.4. Market Attractiveness By Indication
8. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Distribution Channel, 2017-2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others (Compounding Pharmacies, etc.)
8.4. Market Attractiveness By Distribution Channel
9. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Cancer Supportive Care Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Drug Class, 2017-2031
10.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
10.2.2. ESAs (Erythropoiesis Stimulating Agent)
10.2.3. Antiemetics
10.2.4. Bisphosphonates
10.2.5. Opioids
10.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
10.2.7. Others (Topicals, etc.)
10.3. Market Value Forecast By Indication, 2017-2031
10.3.1. Lung Cancer
10.3.2. Breast Cancer
10.3.3. Prostate Cancer
10.3.4. Liver Cancer
10.3.5. Bladder Cancer
10.3.6. Leukemia
10.3.7. Others (Ovarian Cancer, Melanoma, etc.)
10.4. Market Value Forecast By Distribution Channel, 2017-2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others (Compounding Pharmacies, etc.)
10.5. Market Value Forecast By Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Cancer Supportive Care Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Class, 2017-2031
11.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
11.2.2. ESAs (Erythropoiesis Stimulating Agent)
11.2.3. Antiemetics
11.2.4. Bisphosphonates
11.2.5. Opioids
11.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
11.2.7. Others (Topicals, etc.)
11.3. Market Value Forecast By Indication, 2017-2031
11.3.1. Lung Cancer
11.3.2. Breast Cancer
11.3.3. Prostate Cancer
11.3.4. Liver Cancer
11.3.5. Bladder Cancer
11.3.6. Leukemia
11.3.7. Others (Ovarian Cancer, Melanoma, etc.)
11.4. Market Value Forecast By Distribution Channel, 2017-2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others (Compounding Pharmacies, etc.)
11.5. Market Value Forecast By Country, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Indication
11.6.3. By Distribution Channel
11.6.4. By Country
12. Asia Pacific Cancer Supportive Care Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Class, 2017-2031
12.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
12.2.2. ESAs (Erythropoiesis Stimulating Agent)
12.2.3. Antiemetics
12.2.4. Bisphosphonates
12.2.5. Opioids
12.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
12.2.7. Others (Topicals, etc.)
12.3. Market Value Forecast By Indication, 2017-2031
12.3.1. Lung Cancer
12.3.2. Breast Cancer
12.3.3. Prostate Cancer
12.3.4. Liver Cancer
12.3.5. Bladder Cancer
12.3.6. Leukemia
12.3.7. Others (Ovarian Cancer, Melanoma, etc.)
12.4. Market Value Forecast By Distribution Channel, 2017-2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others (Compounding Pharmacies, etc.)
12.5. Market Value Forecast By Country, 2017-2031
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Indication
12.6.3. By Distribution Channel
12.6.4. By Country
13. Latin America Cancer Supportive Care Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Class, 2017-2031
13.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
13.2.2. ESAs (Erythropoiesis Stimulating Agent)
13.2.3. Antiemetics
13.2.4. Bisphosphonates
13.2.5. Opioids
13.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
13.2.7. Others (Topicals, etc.)
13.3. Market Value Forecast By Indication, 2017-2031
13.3.1. Lung Cancer
13.3.2. Breast Cancer
13.3.3. Prostate Cancer
13.3.4. Liver Cancer
13.3.5. Bladder Cancer
13.3.6. Leukemia
13.3.7. Others (Ovarian Cancer, Melanoma, etc.)
13.4. Market Value Forecast By Distribution Channel, 2017-2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Others (Compounding Pharmacies, etc.)
13.5. Market Value Forecast By Country, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Indication
13.6.3. By Distribution Channel
13.6.4. By Country
14. Middle East & Africa Cancer Supportive Care Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Drug Class, 2017-2031
14.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
14.2.2. ESAs (Erythropoiesis Stimulating Agent)
14.2.3. Antiemetics
14.2.4. Bisphosphonates
14.2.5. Opioids
14.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
14.2.7. Others (Topicals, etc.)
14.3. Market Value Forecast By Indication, 2017-2031
14.3.1. Lung Cancer
14.3.2. Breast Cancer
14.3.3. Prostate Cancer
14.3.4. Liver Cancer
14.3.5. Bladder Cancer
14.3.6. Leukemia
14.3.7. Others (Ovarian Cancer, Melanoma, etc.)
14.4. Market Value Forecast By Distribution Channel, 2017-2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Others (Compounding Pharmacies, etc.)
14.5. Market Value Forecast By Country, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Indication
14.6.3. By Distribution Channel
14.6.4. By Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2022)
15.3. Company Profiles
15.3.1. Amgen, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Material Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Merck & Co., Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Material Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Johnson & Johnson Services, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Material Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Heron Therapeutics, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Material Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Novartis AG
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Material Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. GSK plc
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Material Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. F. Hoffmann-La Roche Ltd.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Material Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Helsinn Healthcare SA
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Material Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings